Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
As with any medicine, the MHRA will keep the safety of gepotidacin under close review
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Triggering global regulatory submissions this year for the treatment of obesity
LHP588 is an oral, brain-penetrant lysine-gingipain (Kgp) inhibitor designed to block the key virulence factor of P. gingivalis
Merck will share two oral presentations on ASCVD treatment patterns and patient burden
Protein L is known as a “superantigen” because it can bind antibodies in unusual ways
Guidelines aim to establish state-regulated veterinary blood banks
Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control
Subscribe To Our Newsletter & Stay Updated
